Cerebral perfusion
The sub-study of cerebral perfusion involved only 28 participants, 25 (89.3%) completed the trial: 11 (44%) neuroEPO plus 0.5 mg, 5 (20%) neuroEPO plus 1.0 mg, and 9 (36%) placebo. At baseline, all subjects showed evidence of low cerebral perfusion. At 48 weeks, 63.6% of neuroEPO plus 0.5 mg, 40% of neuroEPO plus 1.0 mg, and 22.2% of placebo group improved their global cerebral perfusion. These results were not significant, 